Randal A. Hassler
Plus aucun poste en cours
Profil
Randal A.
Hassler worked as Vice President-Facility Operations at Amgen, Inc. from 1995 to 2007.
He then worked as Chief Operating Officer, VP-Operations & Finance at Seattle Biomedical Research Institute from 2008 to 2014.
Later, he worked as Executive Vice President-Pharmaceutical Operations at Lundbeck Seattle BioPharmaceuticals, Inc. Mr. Hassler has a graduate degree from Colorado State University and an undergraduate degree from Indiana University.
Anciens postes connus de Randal A. Hassler
| Sociétés | Poste | Fin |
|---|---|---|
Seattle Biomedical Research Institute
 Seattle Biomedical Research Institute Miscellaneous Commercial ServicesCommercial Services Seattle Biomedical Research Institute operates as a non-profit organization that researches and discovers infectious diseases. It provides research for new drugs, vaccines, and diagnostics. The company was founded by Kenneth D. Stuart and Ruth W. Shearer in 1976 and is headquartered in Seattle, WA. | Directeur Financier/CFO | 01/01/2014 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2007 |
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Randal A. Hassler
| Indiana University | Undergraduate Degree |
| Colorado State University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Seattle Biomedical Research Institute
Seattle Biomedical Research Institute Miscellaneous Commercial ServicesCommercial Services Seattle Biomedical Research Institute operates as a non-profit organization that researches and discovers infectious diseases. It provides research for new drugs, vaccines, and diagnostics. The company was founded by Kenneth D. Stuart and Ruth W. Shearer in 1976 and is headquartered in Seattle, WA. | Commercial Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
